Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Better Buy: Biogen vs. Bristol Myers Squibb | The Motley Fool
01:03pm, Sunday, 21'st Jun 2020
Neither drugmaker has been a winner this year. But one appears to be a pretty safe bet to win in the future.
Mackenzie Financial Corp Acquires 8,500 Shares of Akcea Therapeutics Inc (NASDAQ:AKCA)
07:22am, Sunday, 21'st Jun 2020
Mackenzie Financial Corp grew its holdings in Akcea Therapeutics Inc (NASDAQ:AKCA) by 40.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commis
Deutsche Bank AG Has $7 Million Stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
06:26am, Friday, 19'th Jun 2020
Deutsche Bank AG decreased its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 56.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities
BioNano Genomics (BNGO) Receives a Buy from Oppenheimer - Markets
01:33am, Friday, 19'th Jun 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on BioNano Genomics (BNGO – Research Report),
Geron (GERN) Gets a Buy Rating from Needham - Markets
06:37pm, Wednesday, 17'th Jun 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Geron (GERN – Research Report), with
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
11:00am, Wednesday, 17'th Jun 2020
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, tod
Hedge Funds Aren’t Crazy About Ionis Pharmaceuticals, Inc. (IONS) Anymore
01:48am, Wednesday, 17'th Jun 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
Biogen's NURTURE Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BIIB)
08:55am, Tuesday, 16'th Jun 2020
Biogen reports positive data from the NURTURE study. Magenta quits inherited metabolic disorder study. Clovis completes enrolment in RUBRACA study.
Avita Medical (RCEL) Gets a Buy Rating from Oppenheimer - Markets
02:10pm, Monday, 15'th Jun 2020
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Avita Medical (RCEL – Research Report) today and set a price
Akcea: Uninteresting Slow Growth Stock With Long-Term Potential (NASDAQ:AKCA)
05:03pm, Friday, 12'th Jun 2020
AKCA is a highly uninteresting stock - perhaps just the kind we need in these times. It has two approved products and a long pipeline in rare diseases. AKCA is
William Blair Reiterates Their Buy Rating on Neurocrine (NBIX) - Markets
04:15pm, Friday, 12'th Jun 2020
William Blair analyst Myles Minter reiterated a Buy rating on Neurocrine (NBIX – Research Report) on June 8. The company’s
Selecta Biosciences (SELB) Receives a Buy from Needham - Markets
03:49pm, Friday, 12'th Jun 2020
Needham analyst Chad Messer reiterated a Buy rating on Selecta Biosciences (SELB – Research Report) today and set a price
Analysts' Top Healthcare Picks: Regeneron (REGN), IMARA (IMRA) - Markets
03:44pm, Friday, 12'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN
